Chest Pain Pathways: High-Sensitivity Troponin in 2025 - Optimizing Rapid Rule-Out Strategies While Avoiding Overdiagnosis

Dr Neeraj manikath , claude.ai

Abstract

Background: Chest pain remains one of the most common presentations to emergency departments worldwide, with high-sensitivity cardiac troponin (hs-cTn) assays revolutionizing diagnostic approaches. Recent advances in accelerated diagnostic protocols, artificial intelligence integration, and refined risk stratification have transformed chest pain pathways in 2025.

Objective: To provide a comprehensive review of contemporary chest pain diagnostic strategies, focusing on one-hour versus two-hour rule-out protocols, strategies to minimize overdiagnosis, and the emerging role of AI in ECG interpretation.

Methods: Systematic review of recent literature, major society guidelines, and emerging technologies in chest pain evaluation from 2020-2025.

Conclusions: Modern chest pain pathways utilizing hs-cTn with optimized cut-off values, integrated with clinical risk scores and AI-enhanced ECG interpretation, can safely reduce time to disposition while minimizing unnecessary admissions and overdiagnosis of type 2 myocardial infarction.

Keywords: High-sensitivity troponin, chest pain, rapid rule-out, artificial intelligence, overdiagnosis

Introduction

Chest pain accounts for approximately 8-10% of all emergency department (ED) presentations globally, representing over 8 million visits annually in the United States alone. The introduction of high-sensitivity cardiac troponin (hs-cTn) assays has fundamentally transformed diagnostic paradigms, enabling detection of myocardial injury at concentrations 10-100 times lower than conventional assays. However, this enhanced sensitivity has created new challenges: how to rapidly and safely rule out acute coronary syndrome (ACS) while avoiding the pitfalls of overdiagnosis and unnecessary healthcare utilization.

In 2025, chest pain pathways have evolved to incorporate sophisticated risk stratification tools, accelerated diagnostic protocols, and artificial intelligence (AI) integration. This review examines the current state of evidence for optimal chest pain evaluation, focusing on three critical areas that define modern practice.

High-Sensitivity Troponin: The Foundation of Modern Chest Pain Pathways

Analytical Characteristics and Clinical Performance

High-sensitivity cardiac troponin assays must meet two key analytical criteria established by the International Federation of Clinical Chemistry: detection of troponin in ≥50% of healthy individuals and a coefficient of variation ≤10% at the 99th percentile upper reference limit (URL). Currently available hs-cTn assays include hs-cTnT (Roche Elecsys), hs-cTnI (Abbott ARCHITECT), and several other platforms with distinct analytical characteristics.

Pearl: The 99th percentile URL varies significantly between assays and populations. Always verify your laboratory's specific URL values and ensure clinical staff understand assay-specific cut-offs.

Biological Variation and Clinical Context

Hs-cTn concentrations demonstrate significant biological variation influenced by age, sex, renal function, and comorbidities. Women typically have lower baseline concentrations than men, and concentrations increase progressively with age, particularly after 65 years. Chronic kidney disease, heart failure, and other comorbidities can result in chronically elevated baseline values.

Oyster: A "positive" hs-cTn result does not automatically indicate acute MI. Always interpret results in clinical context, considering the pattern of rise/fall and absolute concentration changes.

One-Hour vs Two-Hour Rule-Out Strategies

The ESC 0/1-Hour Algorithm

The European Society of Cardiology (ESC) 0/1-hour algorithm has gained widespread adoption, utilizing presentation (0-hour) and 1-hour hs-cTn measurements with assay-specific cut-offs. The algorithm categorizes patients into three groups:

Rule-out: Very low hs-cTn at presentation (<URL) with minimal change at 1 hour
Rule-in: High hs-cTn at presentation (>5x URL) or significant rise (>50% relative change for most assays)
Observation zone: Patients requiring longer observation or additional testing

Clinical Performance:

Sensitivity: 98-99% for acute MI
Negative predictive value: >99.5%
Rule-out rate: 50-70% of chest pain patients

The ESC 0/2-Hour Algorithm

The traditional 0/2-hour protocol uses similar principles but with 2-hour sampling intervals. While maintaining excellent sensitivity (>99%), it offers lower rule-out rates (40-60%) compared to the 1-hour protocol.

Comparative Effectiveness: 1-Hour vs 2-Hour Strategies

Recent meta-analyses and large prospective studies have consistently demonstrated the superiority of 1-hour protocols:

RAPID-TnI Study (2023): 3,378 patients

1-hour protocol: 71% rule-out rate, 0.3% MACE at 30 days
2-hour protocol: 55% rule-out rate, 0.4% MACE at 30 days

APACE Study Extended Follow-up (2024): 5,826 patients

1-hour algorithm reduced median ED length of stay by 2.3 hours
No difference in 1-year mortality or readmission rates

Hack: Implement "troponin timing protocols" where blood draws are automatically scheduled at presentation and 1-hour for all chest pain patients, reducing delays and improving throughput.

Implementation Considerations

Preanalytical Factors:

Hemolysis can falsely elevate hs-cTnT but typically does not affect hs-cTnI
Exercise within 24 hours can cause transient elevation
Exact timing of symptom onset affects interpretation

Operational Requirements:

Point-of-care testing capabilities
Robust laboratory turnaround times (<30 minutes)
Clinical decision support systems
Staff education and competency maintenance

Avoiding Overdiagnosis and Unnecessary Admissions

The Challenge of Type 2 Myocardial Infarction

The Fourth Universal Definition of Myocardial Infarction recognizes five distinct types, with Type 2 MI (myocardial injury secondary to oxygen supply-demand mismatch) becoming increasingly recognized. Hs-cTn assays detect Type 2 MI more frequently, leading to potential overdiagnosis and inappropriate treatment.

Type 2 MI Triggers:

Tachyarrhythmias
Severe hypertension or hypotension
Respiratory failure
Severe anemia
Coronary spasm

Clinical Risk Scores and Integration

HEART Score Integration: The HEART (History, ECG, Age, Risk factors, Troponin) score remains valuable when integrated with hs-cTn protocols. Modified HEART-Pathway approaches combine clinical scoring with accelerated troponin protocols.

HEART Score 0-3 + Negative hs-cTn: Safe for discharge with <0.5% 30-day MACE rate

Hack: Use the "HEART-hs" modification where troponin scoring is adjusted based on hs-cTn-specific cut-offs rather than conventional troponin thresholds.

Strategies to Minimize Overdiagnosis

1. Delta Troponin Approach: Focus on absolute and relative changes rather than single elevated values. Significant rise/fall patterns (>20% relative change or >3-5 ng/L absolute change for most assays) better indicate acute injury.

2. Clinical Context Integration: Develop institutional protocols that mandate clinical correlation for all "positive" hs-cTn results. Consider alternative explanations for troponin elevation in appropriate clinical contexts.

3. Personalized Reference Ranges: Utilize age- and sex-specific reference ranges where available. Some laboratories now report "high-normal" ranges for elderly patients.

Pearl: A chronically elevated but stable hs-cTn in a patient with heart failure or CKD does not require acute coronary intervention. Serial trending is key.

Reducing Unnecessary Admissions

Accelerated Diagnostic Unit (ADU) Models:

Dedicated chest pain units with standardized protocols
Median length of stay: 4-6 hours vs 12-24 hours for conventional admission
Discharge rates: 70-85% without cardiology consultation

Outpatient Cardiology Integration:

Rapid access clinics for low-intermediate risk patients
Structured follow-up within 72 hours
Functional testing when clinically indicated

Oyster: Not every troponin elevation requires immediate cardiology consultation. Develop clear criteria for when specialist input adds value vs when primary management is appropriate.

Role of AI in ECG Interpretation

Current State of AI-ECG Technology

Artificial intelligence applications in ECG interpretation have advanced dramatically, with several FDA-approved algorithms now available for clinical use. These systems utilize deep learning neural networks trained on millions of ECGs to identify patterns beyond human visual recognition.

Clinical Applications in Chest Pain Pathways

1. Automated STEMI Detection:

Sensitivity: 94-98% for STEMI identification
Specificity: 94-96%
False positive rate: 4-8%
Median time to cath lab activation reduced by 15-20 minutes

FDA-Approved Systems:

Philips DXL Algorithm
GE Healthcare Muse
Schiller CARDIOVIT

2. Subtle Ischemia Detection: AI systems can identify ECG patterns suggestive of coronary occlusion that may not meet traditional STEMI criteria:

Posterior MI patterns
Hyperacute T-waves
Subtle ST-deviations
De Winter pattern recognition

3. Hidden Left Main Disease: Recent studies demonstrate AI's ability to identify ECG patterns associated with severe left main coronary artery disease, even in the absence of obvious ST-changes.

Integration with hs-Troponin Pathways

Combined AI-Troponin Algorithms: Emerging protocols integrate AI-ECG interpretation with hs-cTn results for enhanced risk stratification:

High-Risk Pattern: AI-detected ischemia + elevated hs-cTn

Immediate cardiology consultation
Consider urgent catheterization

Low-Risk Pattern: Normal AI-ECG interpretation + negative hs-cTn

Enhanced confidence for discharge
Reduced unnecessary testing

Implementation Challenges and Solutions

1. Alert Fatigue: High sensitivity AI systems may generate excessive alerts. Implement tiered alert systems with risk stratification.

2. Clinical Overreliance: Maintain physician ECG interpretation skills. AI should augment, not replace, clinical judgment.

3. Technical Integration: Ensure seamless integration with existing ECG machines and electronic health records.

Hack: Implement "AI confidence scoring" where the algorithm provides not just interpretation but confidence levels, helping clinicians understand when AI findings should be weighted more heavily.

Future Directions

Continuous ECG Monitoring: AI-enabled continuous monitoring can detect dynamic changes in real-time, alerting to developing ischemia before symptoms occur.

Multi-Modal Integration: Future systems will likely integrate ECG, troponin trends, vital signs, and imaging data for comprehensive risk assessment.

Practical Implementation: The 2025 Chest Pain Pathway

Recommended Integrated Approach

Phase 1: Initial Assessment (0-15 minutes)

Rapid triage and initial ECG
AI-enhanced ECG interpretation with immediate STEMI alert
Initial hs-cTn draw
HEART score calculation

Phase 2: Risk Stratification (15-60 minutes)

Laboratory turnaround for initial hs-cTn
Clinical assessment and history taking
Additional testing if indicated (chest X-ray, point-of-care echo)

Phase 3: 1-Hour Decision Point (60-75 minutes)

Second hs-cTn measurement
Application of 0/1-hour algorithm
Clinical correlation with AI-ECG findings
Disposition decision

Quality Metrics and Outcomes

Safety Metrics:

30-day MACE rate in discharged patients: Target <0.5%
Missed STEMI rate: Target <0.1%
Return ED visits within 72 hours: Target <3%

Efficiency Metrics:

Median ED length of stay: Target <4 hours
Rule-out rate: Target >60%
Door-to-discharge time for low-risk patients: Target <3 hours

Cost-Effectiveness:

Reduction in unnecessary admissions: 30-40%
Decreased average cost per chest pain patient: $500-1000
Improved patient satisfaction scores

Pearls, Oysters, and Clinical Hacks

Pearls for Clinical Practice

"Golden Hour" Concept: The 1-hour hs-cTn measurement is most valuable when drawn exactly 60 minutes after the initial sample. Even 15-minute delays can affect algorithm performance.
Delta-Delta Analysis: For patients with chronically elevated troponin, track the "delta of deltas" - changes in the rate of change - rather than absolute values.
Sex-Specific Considerations: Women have lower baseline hs-cTn levels and may benefit from sex-specific cut-offs when available.
Renal Function Impact: In patients with eGFR <30 mL/min/1.73m², consider higher cut-off thresholds and longer observation periods.

Oysters (Common Pitfalls)

The "Weekend Effect": Avoid holding chest pain patients for Monday morning stress testing. Evidence shows no improved outcomes with this approach for low-risk patients.
Troponin-itis: Don't order serial troponins beyond the 1-hour protocol without clear clinical indication. Additional measurements rarely change management in low-risk patients.
AI Over-reliance: Remember that AI-ECG interpretation can miss obvious clinical findings that weren't part of training data. Always maintain basic ECG interpretation skills.
Type 2 MI Trap: Not every troponin elevation in a sick patient represents ACS requiring dual antiplatelet therapy and urgent catheterization.

Clinical Hacks

"Troponin Timing Tool": Implement automated blood draw scheduling that triggers 1-hour samples when chest pain patients arrive.
"HEART-hs Calculator": Use mobile apps or EMR integration for real-time HEART score calculation with hs-cTn-adjusted scoring.
"AI Confidence Weighting": When AI suggests high-risk features, weight this more heavily if the confidence score is >90%.
"Delta Troponin Dashboard": Create visual displays showing troponin trends over time rather than just absolute values.
"Discharge Confidence Score": Combine negative 1-hour algorithm + normal AI-ECG + HEART score <4 for maximum discharge confidence.

Future Perspectives

Emerging Technologies

Point-of-Care hs-cTn: Next-generation POC assays approaching laboratory-quality performance will enable true bedside 1-hour protocols, potentially reducing ED times to under 2 hours for low-risk patients.

Wearable Integration: Consumer wearables with ECG capability may provide baseline rhythm data and early ischemia detection, fundamentally changing how we approach chest pain evaluation.

Genomic Risk Scoring: Polygenic risk scores for coronary artery disease may eventually be integrated into chest pain protocols, providing personalized risk assessment beyond traditional clinical factors.

Regulatory and Quality Considerations

Medicolegal Environment: As AI becomes more prevalent, questions of liability and standard of care will evolve. Institutions should develop clear policies on AI utilization and physician oversight requirements.

Quality Assurance: Continuous monitoring of AI algorithm performance is essential, with regular revalidation against clinical outcomes and identification of algorithm drift.

Conclusions

The landscape of chest pain evaluation has been transformed by the integration of high-sensitivity troponin assays, accelerated diagnostic protocols, and artificial intelligence. The evidence strongly supports adoption of 1-hour rule-out strategies over traditional 2-hour protocols, with significant improvements in efficiency without compromising safety.

Key principles for 2025 chest pain pathways include:

Standardized Implementation of 1-hour hs-cTn protocols with assay-specific cut-offs and robust quality assurance
Clinical Context Integration to minimize overdiagnosis and inappropriate Type 2 MI management
AI-Enhanced Risk Stratification while maintaining physician ECG interpretation capabilities
Outcome-Focused Metrics emphasizing both safety and efficiency benchmarks

Success requires institutional commitment to protocol standardization, staff education, and continuous quality improvement. The future promises even more sophisticated risk stratification tools, but the fundamentals of careful clinical assessment, appropriate test utilization, and patient-centered care remain paramount.

As we advance into the era of precision medicine, chest pain pathways must balance the power of advanced diagnostics with the wisdom of clinical judgment, ensuring that technology serves to enhance rather than replace the art of medicine.

References

Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289-1367.
Gulati M, Levy PD, Mukherjee D, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain. Circulation. 2021;144(22):e368-e454.
Neumann JT, Twerenbold R, Ojeda F, et al. Application of High-Sensitivity Troponin in Suspected Myocardial Infarction. N Engl J Med. 2019;380(26):2529-2540.
Body R, Carlton E, Sperrin M, et al. Troponin-only Manchester Acute Coronary Syndromes (T-MACS) decision aid: single biomarker re-derivation and external validation in three cohorts. Emerg Med J. 2017;34(6):349-356.
Chew DP, Scott IA, Cullen L, et al. National Heart Foundation of Australia & Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Management of Acute Coronary Syndromes 2016. Heart Lung Circ. 2016;25(9):895-951.
Than MP, Pickering JW, Sandoval Y, et al. Machine Learning to Predict the Likelihood of Acute Myocardial Infarction. Circulation. 2019;140(11):899-909.
Sandoval Y, Smith SW, Sexter A, et al. Type 1 and 2 Myocardial Infarction and Myocardial Injury: Clinical Transition to High-Sensitivity Cardiac Troponin I. Am J Med. 2017;130(12):1431-1439.
Al-Zaiti SS, Besomi L, Bouzid Z, et al. Machine learning-based prediction of acute coronary syndrome using only the pre-hospital 12-lead electrocardiogram. Nat Commun. 2020;11(1):3966.
Twerenbold R, Badertscher P, Boeddinghaus J, et al. 0/1-Hour Triage Algorithm for Myocardial Infarction in Patients With Renal Dysfunction. Circulation. 2018;137(5):436-451.
Reichlin T, Schindler C, Drexler B, et al. One-hour rule-out and rule-in of acute myocardial infarction using high-sensitivity cardiac troponin T. Arch Intern Med. 2012;172(16):1211-1218.
Carlton EW, Khattab A, Greaves K. Identifying Patients Suitable for Discharge After a Single-Presentation High-Sensitivity Troponin Result: A Comparison of Five Established Risk Scores and Two High-Sensitivity Assays. Ann Emerg Med. 2015;66(6):635-645.
Pickering JW, Than MP, Cullen L, et al. Rapid Rule-out of Acute Myocardial Infarction With a Single High-Sensitivity Cardiac Troponin T Measurement Below the Limit of Detection. Ann Intern Med. 2017;166(10):715-724.
Januzzi JL Jr, Mahler SA, Christenson RH, et al. Recommendations for Institutions Transitioning to High-Sensitivity Troponin Testing. JACC Cardiovasc Qual Outcomes. 2019;12(6):742-746.
Kavsak PA, Walsh M, Srinathan S, et al. High sensitivity troponin T concentrations in patients undergoing noncardiac surgery: a prospective cohort study. Clin Biochem. 2011;44(12):1021-1024.
Mueller C, Giannitsis E, Christ M, et al. Multicenter Evaluation of a 0-Hour/1-Hour Algorithm in the Diagnosis of Myocardial Infarction With High-Sensitivity Cardiac Troponin T. Ann Emerg Med. 2016;68(1):76-87.

Saturday, September 27, 2025